Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Eligible for Cisplatin Therapy
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 10 Mar 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2021.
- 10 Mar 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 05 May 2016 Status changed from not yet recruiting to recruiting.